Dashboard
1
Weak Long Term Fundamental Strength as the company has not declared results in the last 6 months
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -0.72
2
The company has declared Negative results for the last 4 consecutive quarters
3
Risky - Negative EBITDA
4
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
CAD 21 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.56
91.50%
-3.86
Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - May 2025)
Net Profit:
-1 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-11.11%
0%
-11.11%
6 Months
-38.46%
0%
-38.46%
1 Year
-27.27%
0%
-27.27%
2 Years
6.67%
0%
6.67%
3 Years
-20.0%
0%
-20.0%
4 Years
-44.83%
0%
-44.83%
5 Years
-34.69%
0%
-34.69%
Rapid Dose Therapeutics Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-78.88%
EBIT Growth (5y)
-164.79%
EBIT to Interest (avg)
-0.73
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.50
Sales to Capital Employed (avg)
-2,127.70
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
6,711.89%
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-3.98
EV to EBIT
-6.50
EV to EBITDA
-7.05
EV to Capital Employed
-10.39
EV to Sales
9.80
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - May'25 - QoQ
May'25
Nov'24
Change(%)
Net Sales
0.80
0.50
60.00%
Operating Profit (PBDIT) excl Other Income
-0.40
-1.00
60.00%
Interest
0.20
0.30
-33.33%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-0.70
-1.40
50.00%
Operating Profit Margin (Excl OI)
-644.00%
-2,026.60%
138.26%
USD in Million.
Net Sales
Not Applicable: The company has declared_date for only one period
Consolidated Net Profit
Not Applicable: The company has declared_date for only one period
Annual Results Snapshot (Consolidated) - Feb'25
Feb'25
Feb'24
Change(%)
Net Sales
2.10
1.00
110.00%
Operating Profit (PBDIT) excl Other Income
-3.90
-2.50
-56.00%
Interest
1.20
0.70
71.43%
Exceptional Items
0.00
-0.60
100.00%
Consolidate Net Profit
-5.40
-4.30
-25.58%
Operating Profit Margin (Excl OI)
-2,000.70%
-3,021.60%
102.09%
USD in Million.
Net Sales
YoY Growth in year ended Feb 2025 is 110.00% vs 42.86% in Feb 2024
Consolidated Net Profit
YoY Growth in year ended Feb 2025 is -25.58% vs -13.16% in Feb 2024
About Rapid Dose Therapeutics Corp. 
Rapid Dose Therapeutics Corp.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






